A global research priority agenda to advance public health responses to fatty liver disease

Francque, Sven; Hagström, Hannes; Lazarus, Jeffrey V.; Mark, Henry E.; Allen, Alina M.; Arab, Juan Pablo; Carrieri, Patrizia; Noureddin, Mazen; Alazawi, William; Loomba, Rohit; Alqahtani, Saleh A.; Arrese, Marco; Bataller, Ramón; Berg, Thomas; Brennan, Paul; Burra, Patrizia; Castro-Narro, Graciela; Cortez‐Pinto, Helena; Cusi, Kenneth; Dedes, Nikos; Duseja, Ajay; Hagström, Sven M. Francque Hannes; Huang, Terry T.‐K.; Wajcman, Dana Ivancovsky; Kautz, Achim; Kopka, Christopher J.; Krag, Aleksander; Miller, Veronica; Newsome, Philip N.; Rinella, Mary E.; Romero, Diana; Sarin, Shiv Kumar; Silva, Marcelo; Spearman, Wendy; Tsochatzis, Emmanuel; Valenti, Luca; Villota-Rivas, Marcela; Zelber‐Sagi, Shira; Schattenberg, Jörn M.; Wong, Vincent Wai‐Sun; Younossi, Zobair M.; Åberg, Fredrik; Adams, Leon A.; Al-Naamani, Khalid; Albadawy, Reda; Alexa, Zinaida; Allison, Michael; Alnaser, Faisal Abdullatif; Alswat, Khalid; Álvares‐da‐Silva, Mário Reis; Alvaro, Domenico; Auger, Michèle; Andrade, Raúl J.; Awuku, Yaw Asante; Baatarkhuu, Oidov; Baffy, György; Bakieva, Shokhista; Bansal, Meena B.; Barouki, Robert; Batterham, Rachel L.; Behling, Cynthia; Belfort-DeAguiar, Renata; Anstee, Quentin M.; Betel, Michael; Bianco, Cristiana; Bosi, Emanuele; Boursier, Jérôme; Brunt, Elizabeth M.; Bugianesi, Elisabetta; Byrne, Christopher J.; Cabrejos, Maria Cecilia Cabrera; Caldwell, Stephen H.; Carr, Rotonya M.; Fernández, Marlen Ivón Castellanos; Castéra, Laurent; Castillo-López, M G; Caussy, Cyrielle; Cerda-Reyes, Eira; Ceriello, Antonio; Chan, Wah Kheong; Chang, Yoosoo; Charatcharoenwitthaya, Phunchai; Chávez-Tapia, Norberto C.; Chung, Raymond T.; Colombo, Massimo; Coppell, Kirsten J; Cotrim, Helma Pinchemel; Craxı̀, Antonio; Crespo, Javier; Dassanayake, Anuradha S; Davidson, Nicholas O.; Knegt, Robert J. de; Lédinghen, Victor de; Demir, Münevver; Desalegn, Hailemichael; Diago, M.; Dillon, John; Dimmig, Bruce; Dirac, M Ashworth; Dirchwolf, Melisa; Dufour, Jean–François; Dvořák, Karel; Ekstedt, Mattias; Kassas, Mohamed El; Elsanousi, Osama M.; Elsharkawy, Ahmed M.; Elwakil, Reda; Eskridge, Wayne; Eslam, Mohammed; Esmat, Gamal; Fan, Jian Gao; Ferraz, Maria Lúcia Gomes; Flisiak, Robert; Fortin, Davide; Fouad, Yasser; Freĭdman, S L; Fuchs, Michael; Gadano, Adrián; Gastaldelli, Amalia; Geerts, Anja; Geier, Andreas; George, Jacob; Gerber, Lynn H.; Ghazinyan, Hasmik; Gheorghe, Liana; Kile, Denise Giangola; Girala, Marcos; Goh, George Boon-Bee; Goossens, Nicolas; Graupera, Isabel; Grønbæk, Henning; Salehiniya, Hamid; Hebditch, Vanessa; Henry, Zachary; Hickman, Ingrid J.; Hobbs, Lorna; Hocking, Samantha; Hofmann, Wolf Peter; İdilman, Ramazan; Iruzubieta, Paula; Isaacs, Scott; Isakov, Vasily; Ismail, Mona H; Jamal, Mohammad H.; Jarvis, Helen; Jepsen, Peter; Jornayvaz, François R.; Sudhamshu, K C; Kakizaki, Satoru; Karpen, Saul J.; Kawaguchi, Takumi; Keating, Shelley E.; Khader, Yousef; Kim, Seung Up; Kim, Won; Kleiner, David E.; Koek, Ger H.; Komas, Narcisse; Kondili, Loreta A.; Koot, Bart; Korenjak, Marko; Kotsiliti, Eleni; Koulla, Yiannoula; Kugelmas, Carina; Kugelmas, Marcelo; Labidi, A.; Lange, Naomi; Lavine, Joel E.; Lazo, Mariana; Leite, Nathalie C.; Lin, Han‐Chieh; Lkhagvaa, Undram; Long, Michelle T.; López‐Jaramillo, Patricio; Lozano, Adelina; Macedo, M. Paula; Malekzadeh, Reza; Marchesini, Giulio; Marciano, Sebastián; Martínez, Kim; Vazquez, S; Mateva, Lyudmila; Mato, José M.; Nlombi, Charles Mbendi; McCary, Alexis Gorden; McIntyre, James; McKee, Martin; Mendive, Juan Manuel; Mikolašević, Ivana; Miller, Pamela S.; Milovanović, Tamara; Milton, Terri; Moreno-Alcántar, R.; Morgan, Timothy R.; Motala, Ayesha A.; Muris, Jean; Musso, Carla; Nava‐González, Edna J.; Negro, Francesco; Nersesov, Alexander; Neuschwander‐Tetri, Brent A.; Nikolova, Dafina; Norris, Suzanne; Novak, Katarina; Ocama, Ponsiano; Ong, Janus P.; Ong-Go, Arlinking K.; Onyekwere, Charles; Padilla, Martín; Pais, Raluca; Pan, Calvin Q.; Panduro, Arturo; Panigrahi, Manas; Papatheodoridis, Georgios; Paruk, Imran; Patel, Keyur; Gonçalves, Cláudia Giglio de Oliveira; Figueroa, M; Pérez-Escobar, Juanita; Pericàs, Juan M.; Perseghin, Gianluca; Pessôa, Mário; Petta, Salvatore; Oliveira, Cláudia Pinto Marques Souza de; Prabhakaran, Dorairaj; Pyrsopoulous, Nikolaos; Rabiee, Atoosa; Ramji, Alnoor; Ratziu, Vlad; Ravendhran, Natarajan; Ray, Katrina; Roden, Michael; Romeo, Stefano; Romero–Gómez, Manuel; Rotman, Yaron; Rouabhia, Samir; Rowe, Ian; Sadirova, Shakhlo; Alkhatry, Maryam; Salupere, Riina; Satapathy, Sanjaya K.; Schwimmer, Jeffrey B.; Sebastiani, Giada; Seim, Lynn; Seki, Yosuke; Sermé, Abdel Karim; Shapiro, D. A.; Sharvadze, Lali; Shaw, Jonathan E.; Shawa, Isaac Thom; Shenoy, T Sheela; Shibolet, Oren; Shimakawa, Yusuke; Shubrook, Jay H.; Singh, Shivaram Prasad; Sinkala, Edford; Skladaný, Ľubomír; Skrypnyk, І. М.; Song, Myeong Jun; Sookoian, Silvia; Sridharan, Kannan; Stefan, Norbert; Stine, Jonathan G.; Stratakis, Nikos; Sheriff, Dhastagir Sultan; Sundaram, Shikha S.; Svegliati‐Baroni, Gianluca; Swain, Mark G.; Tacke, Frank; Taheri, Shahrad; Tan, Soek‐Siam; Tapper, Elliot B.; Targher, Giovanni; Tcaciuc, Eugen; Thiele, Maja; Tiniakos, Dina; Tolmane, Ieva; Torre, Aldo; Torres, Esther A.; Treeprasertsuk, Sombat; Trenell, Michael I.; Turcan, Svetlana; Turcanu, Adela; Valantinas, Jonas; Kleef, Laurens A. van; Velasco, José Antonio Velarde Ruiz; Vesterhus, Mette; Vilar‐Gomez, Eduardo; Waked, Imam; Wattacheril, Julia; Wedemeyer, Heiner; Wilkins, Fonda; Willemse, J.; Wong, Robert J.; Yılmaz, Yusuf; Yki‐Järvinen, Hannele; Yu, Ming; Yumuk, Volkan; Zeybel, Müjdat; Zheng, Kenneth I.; Zheng, Ming‐Hua

doi:10.1016/j.jhep.2023.04.035

Cited by 58 publications

(30 citation statements)

References 92 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Along with the evolving refinement of NITs and referral pathways, the panel agreed on the importance of standardization around key effectiveness measures to be used in the evaluation of multidisciplinary models of care (priority 2.7). These priorities sit alongside previous calls to generate data to validate NITs for early diagnosis, prognosis, and monitoring of liver disease progression 16 …”

Section: Discussionmentioning

confidence: 96%

“…The same global consortium previously published 28 research priorities following the same methodology. [16] The 9 co-chairs identified 33 experts, covering clinical care and research, public health and policy, and advocacy, who collectively formed the core author group (n = 42) (Supplementary Table 1, http://links. lww.com/HEP/H907).…”

Section: Methodsmentioning

confidence: 99%

“…Each action priority was graded to indicate the level of combined agreement ("agree" + "somewhat agree"), using a system that has been used in other Delphi studies [13] in which "U" denotes unanimous (100%) agreement, "A" denotes 90%-99% combined agreement, "B" denotes 78%-89% combined agreement, and "C" denotes 67%-77% combined agreement. For the ranking, scores were calculated and normalized in Microsoft Excel (v. 16.70) to compare rankings within each domain.…”

Section: Delphi Methods Data Collection and Analysismentioning

confidence: 99%

“…This study employed a Delphi methodology to develop consensus action priorities for fatty liver disease. The same global consortium previously published 28 research priorities following the same methodology 16 …”

Section: Methodsmentioning

confidence: 99%

“…These priorities sit alongside previous calls to generate data to validate NITs for early diagnosis, prognosis, and monitoring of liver disease progression. [16] Recognizing the shift within public policy and health systems toward person-centered care, [26,27] engaging affected populations in the development of patientcentered care pathways (priority 2.1) and implementing community-tailored models of care for diagnosis, prevention, and treatment (priority 2.2, ranked 3rd in its domain) were determined to be priorities.…”

Section: Domain 2: Defining and Implementing Models Of Carementioning

confidence: 99%

See 4 more Smart Citations

A global action agenda for turning the tide on fatty liver disease

et al. 2023

Self Cite

View full text Add to dashboard Cite

Background & Aims: Fatty liver disease is a major public health threat due to its very high prevalence and related morbidity and mortality. Focused and dedicated interventions are urgently needed to target disease prevention, treatment, and care. Approach & Results: We developed an aligned, prioritized action agenda for the global fatty liver disease community of practice. Following a Delphi methodology over two rounds a large panel (R1 n = 344, R2 n = 288) reviewed the action priorities, via Qualtrics XM, indicating agreement using a four-point Likert-scale and providing written feedback. Priorities were revised between rounds and in R2 panelists also ranked the priorities within six domains: epidemiology, treatment and care, models of care, education and awareness, patient and community perspectives, and leadership and public health policy. The consensus fatty liver disease action agenda encompasses 29 priorities. In R2 the mean percentage of ‘agree’ responses was 82.4%, with all individual priorities having at least a super-majority of agreement (> 66.7% ‘agree’). The highest ranked action priorities included collaboration between liver specialists and primary care doctors on early diagnosis, action to address the needs of people living with multiple morbidities, and the incorporation of fatty liver disease into relevant non-communicable disease strategies and guidance. Conclusions: This consensus driven multidisciplinary fatty liver disease action agenda developed by care providers, clinical researchers, and public health and policy experts provides a path to reducing fatty liver disease prevalence and improve health outcomes. To implement this agenda, concerted efforts will be needed at the global, regional, and national levels.

show abstract

Section: Discussionmentioning

confidence: 96%

Section: Methodsmentioning

confidence: 99%

Section: Delphi Methods Data Collection and Analysismentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Domain 2: Defining and Implementing Models Of Carementioning

confidence: 99%

See 3 more Smart Citations

A global action agenda for turning the tide on fatty liver disease

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

Paternal preconceptional supplementation of n‐3 polyunsaturated fatty acids alleviates offspring nonalcoholic fatty liver disease in high‐fat diet‐induced obese mice

Shi,

Fan,

Yang

et al. 2024

Food Frontiers

View full text Add to dashboard Cite

Exposure to nutritional or environmental factors in early life determines susceptibility to nonalcoholic fatty liver disease (NAFLD). The effect of paternal preconceptional n‐3 polyunsaturated fatty acids (n‐3 PUFAs) on offspring NAFLD development remains unknown. Herein, a mouse model that weaning male mice (F0) received diet supplementation of normal n‐3 PUFA content (n‐6:n‐3 PUFA ratio = 4.3:1) or high n‐3 PUFA content (n‐6:n‐3 ratio = 1.5:1) for 12 weeks, and an n‐3 PUFA‐deficient diet as control, was used for the production of next generation. The F1 and F2 offspring were generated by mating F0 and F1 male mice with virgin female mice, respectively, and after weaning, were fed a high‐fat diet to induce NAFLD. The paternal n‐3 PUFA supplementation improved the scores of steatosis, inflammation and ballooning, and the fibrosis in the liver of two generations, with expressional upregulation of genes associated with fat oxidation (Atgl, Ppara, or Cpt1a), and downregulation of inflammatory genes (Ccl2, Tnf‐α, F4/80, CD206, or CD11c) and fibrosis genes (Tgf‐β, Timp1, or Col1a1). The lessened brown adipose tissue whitening, altered gut bacterial compositions, and altered expression of the imprinted genes (H19, Igf2, and Plagl1) might mediate the impact of paternal n‐3 PUFAs on offspring's NAFLD development, which was dose‐dependent. The data indicate that preconceptional higher paternal intake of n‐3 PUFAs might have intergenerational and transgenerational alleviating impact on obesity‐associated NAFLD development in the offspring through multiple pathways.

show abstract

Utilization and perspectives of weight loss medications in pediatric metabolic dysfunction‐associated steatotic liver disease

Kehar,

Ibrahim,

Ramirez

et al. 2024

J. pediatr. gastroenterol. nutr.

View full text Add to dashboard Cite

Metabolic dysfunction‐associated steatotic liver disease (MASLD) is increasing globally in pediatric populations. Currently, MASLD management primarily relies on lifestyle interventions, which pose challenges in sustaining long‐term weight loss. This study investigated the use of weight loss medications in MASLD care through an international survey of 166 pediatric gastroenterologists and hepatologists. The results indicated a notable interest in weight loss medications, with 38% of practitioners considering or using them, particularly glucagon‐like peptide‐1 receptor agonists. However, the survey also revealed a tendency among clinicians to refer patients to specialists, emphasizing the potential gap between acknowledgment and prescription practices. Challenges include the lack of guidelines and uncertainty regarding side effects. The study highlights a pressing need for education, with over 90% of the respondents expressing an interest. Our study highlights the current management of MASLD, the potential role of pharmacotherapy, and highlights avenues for improved care and education in this dynamic field.

show abstract

A global research priority agenda to advance public health responses to fatty liver disease

Cited by 58 publications

References 92 publications

A global action agenda for turning the tide on fatty liver disease

A global action agenda for turning the tide on fatty liver disease

Paternal preconceptional supplementation of n‐3 polyunsaturated fatty acids alleviates offspring nonalcoholic fatty liver disease in high‐fat diet‐induced obese mice

Utilization and perspectives of weight loss medications in pediatric metabolic dysfunction‐associated steatotic liver disease

Contact Info

Product

Resources

About